Synergistic Impact of 25-Hydroxyvitamin D Level and Obesity on the Risk of Metabolic Syndrome

IF 2.2 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

International Journal of Clinical Practice Pub Date : 2025-03-21 DOI:10.1155/ijcp/6634233

Tsui-Yen Chang, Jong-Dar Chen

{"title":"Synergistic Impact of 25-Hydroxyvitamin D Level and Obesity on the Risk of Metabolic Syndrome","authors":"Tsui-Yen Chang, Jong-Dar Chen","doi":"10.1155/ijcp/6634233","DOIUrl":null,"url":null,"abstract":"<div>\n Background: The global increase in the prevalence of metabolic syndrome (MetS), which is defined by impaired glucose homeostasis, visceral obesity, hypertension, and dyslipidemia, presents a significant health concern. Obesity is a primary risk factor for MetS, and low vitamin D levels have been linked to several metabolic disorders. Given the high prevalence of vitamin D deficiency among individuals with obesity, this study examined the combined influence of vitamin D deficiency and obesity on the risk of MetS.\n Methods: This cross-sectional study was conducted from January 2021 to December 2022 at Shin Kong Memorial Hospital. A total of 7248 participants underwent physical examinations, including measurements of fasting glucose levels, lipid profiles, and serum 25-hydroxyvitamin D levels. Participants were categorized into six groups according to vitamin D status (deficiency < 50 nmol/L, insufficiency 50–74.9 nmol/L, and sufficiency ≥ 75 nmol/L) and body mass index (BMI; nonobese < 27 kg/m2 and obese ≥ 27 kg/m2).\n Results: Vitamin D levels were significantly lower in younger patients, women, those with BMI ≥ 27 kg/m2, and those who engaged in exercise less frequently. Patients with vitamin D sufficiency and without obesity constituted the reference group. Vitamin D level was inversely associated with MetS (odds ratio [OR] = 1.7 and 95% confidence interval [CI]: 1.4–2.0), with a stronger association in individuals with obesity (OR = 9.2 and 95% CI: 7.9–10.7). The highest risk was observed in patients with both vitamin D deficiency and obesity (OR = 13.7). Vitamin D deficiency and obesity were found to synergistically influence MetS (synergy index: 1.3 and 95% CI: 1.0–1.7). Notably, the association between vitamin D deficiency and MetS was nonsignificant in patients without obesity.\n Conclusions: Both vitamin D deficiency and obesity are independently associated with MetS, with a synergistic effect observed when both conditions are present.\n </div>","PeriodicalId":13782,"journal":{"name":"International Journal of Clinical Practice","volume":"2025 1","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ijcp/6634233","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/ijcp/6634233","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The global increase in the prevalence of metabolic syndrome (MetS), which is defined by impaired glucose homeostasis, visceral obesity, hypertension, and dyslipidemia, presents a significant health concern. Obesity is a primary risk factor for MetS, and low vitamin D levels have been linked to several metabolic disorders. Given the high prevalence of vitamin D deficiency among individuals with obesity, this study examined the combined influence of vitamin D deficiency and obesity on the risk of MetS.

Methods: This cross-sectional study was conducted from January 2021 to December 2022 at Shin Kong Memorial Hospital. A total of 7248 participants underwent physical examinations, including measurements of fasting glucose levels, lipid profiles, and serum 25-hydroxyvitamin D levels. Participants were categorized into six groups according to vitamin D status (deficiency < 50 nmol/L, insufficiency 50–74.9 nmol/L, and sufficiency ≥ 75 nmol/L) and body mass index (BMI; nonobese < 27 kg/m² and obese ≥ 27 kg/m²).

Results: Vitamin D levels were significantly lower in younger patients, women, those with BMI ≥ 27 kg/m², and those who engaged in exercise less frequently. Patients with vitamin D sufficiency and without obesity constituted the reference group. Vitamin D level was inversely associated with MetS (odds ratio [OR] = 1.7 and 95% confidence interval [CI]: 1.4–2.0), with a stronger association in individuals with obesity (OR = 9.2 and 95% CI: 7.9–10.7). The highest risk was observed in patients with both vitamin D deficiency and obesity (OR = 13.7). Vitamin D deficiency and obesity were found to synergistically influence MetS (synergy index: 1.3 and 95% CI: 1.0–1.7). Notably, the association between vitamin D deficiency and MetS was nonsignificant in patients without obesity.

Conclusions: Both vitamin D deficiency and obesity are independently associated with MetS, with a synergistic effect observed when both conditions are present.

Abstract Image

查看原文本刊更多论文

25-羟基维生素D水平与肥胖对代谢综合征风险的协同影响

背景：代谢综合征（MetS）的全球患病率增加，由葡萄糖稳态受损、内脏肥胖、高血压和血脂异常定义，引起了重大的健康问题。肥胖是代谢障碍的主要危险因素，维生素D水平低与几种代谢紊乱有关。鉴于维生素D缺乏在肥胖人群中的高发率，本研究考察了维生素D缺乏和肥胖对MetS风险的综合影响。方法：本横断面研究于2021年1月至2022年12月在新光纪念医院进行。共有7248名参与者接受了体检，包括空腹血糖水平、脂质谱和血清25-羟基维生素D水平的测量。参与者根据维生素D状况（缺乏）被分为六组；50 nmol/L，不足50 - 74.9 nmol/L，充足≥75 nmol/L)和体重指数(BMI；nonobese & lt;27 kg/m2和肥胖≥27 kg/m2)。结果：年轻患者、女性、BMI≥27 kg/m2和运动频率较低的患者维生素D水平明显较低。对照组为维生素D充足且无肥胖的患者。维生素D水平与MetS呈负相关（比值比[OR] = 1.7, 95%可信区间[CI]: 1.4-2.0），与肥胖个体的相关性更强（OR = 9.2, 95% CI: 7.9-10.7）。维生素D缺乏和肥胖患者的风险最高（OR = 13.7）。发现维生素D缺乏和肥胖协同影响MetS（协同指数：1.3,95% CI: 1.0-1.7）。值得注意的是，在没有肥胖的患者中，维生素D缺乏和MetS之间的关联不显著。结论：维生素D缺乏和肥胖都与MetS独立相关，当两者同时存在时，可以观察到协同效应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Clinical Practice 医学-医学：内科

CiteScore

5.30

自引率

0.00%

发文量

274

审稿时长

3-8 weeks

期刊介绍： IJCP is a general medical journal. IJCP gives special priority to work that has international appeal. IJCP publishes: Editorials. IJCP Editorials are commissioned. [Peer reviewed at the editor''s discretion] Perspectives. Most IJCP Perspectives are commissioned. Example. [Peer reviewed at the editor''s discretion] Study design and interpretation. Example. [Always peer reviewed] Original data from clinical investigations. In particular: Primary research papers from RCTs, observational studies, epidemiological studies; pre-specified sub-analyses; pooled analyses. [Always peer reviewed] Meta-analyses. [Always peer reviewed] Systematic reviews. From October 2009, special priority will be given to systematic reviews. [Always peer reviewed] Non-systematic/narrative reviews. From October 2009, reviews that are not systematic will be considered only if they include a discrete Methods section that must explicitly describe the authors'' approach. Special priority will, however, be given to systematic reviews. [Always peer reviewed] ''How to…'' papers. Example. [Always peer reviewed] Consensus statements. [Always peer reviewed] Short reports. [Always peer reviewed] Letters. [Peer reviewed at the editor''s discretion] International scope IJCP publishes work from investigators globally. Around 30% of IJCP articles list an author from the UK. Around 30% of IJCP articles list an author from the USA or Canada. Around 45% of IJCP articles list an author from a European country that is not the UK. Around 15% of articles published in IJCP list an author from a country in the Asia-Pacific region.